Name change to Vaxzevria from COVID-19 Vaccine AstraZeneca

The brand name Vaxzevria has now been registered for use in Australia for AstraZeneca’s COVID-19 vaccine (previously COVID-19 Vaccine AstraZeneca). The brand name Vaxzevria is already approved by regulatory agencies around the world including the European Medicines Agency (EMA) as well as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. 

Use of the Vaxzevria brand name should help simplify international travel for people vaccinated with AstraZeneca’s vaccine. The vaccine has previously received emergency authorisation from the World Health Organisation. As such Vaxzevria, including Vaxzevria produced at CSL in Australia, is a valid vaccination for travel to Europe.

AstraZeneca's COVID-19 vaccine is the same product wherever it is made. All manufacturing around the world is conducted using the same stringent manufacturing process and each batch passes over 60 quality tests as part of our global robust quality assurance process.

In Australia, people can expect to see both names, Vaxzevria and COVID-19 Vaccine AstraZeneca, used for the coming months. The change to a permanent trade name has been planned for many months, and has no impact on the vaccine’s approval status, supply and delivery timings, or AstraZeneca’s commitment to provide broad and equitable access to the vaccine at no profit during the pandemic period.

AU-11419; prepared August 2021